Sandoz voluntarily recalls 24 lots of injectable methotrexate

10/27/2010 | Reuters

Novartis' Sandoz unit is recalling 24 lots of methotrexate, an injectable chemotherapy drug, after discovering glass particulates in the product. The recall affects vials of 50 milligrams per 2 milliliters and 250 milligrams per 10 milliliters. Sandoz has not received reports of adverse effects concerning the drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA